138 results for "psycinfo"
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Healthcare – March 03, 2026
Summary
Ketamine shows potential as a rapid treatment for acute suicidality, offering relief within hours compared to the 2-6 weeks required for traditional SSRIs. With suicide rates rising in the U.S., this is a crucial public health concern. A review of literature, including data from MEDLINE and PsycINFO, highlights that supervised subanesthetic doses of Ketamine pose low risks of addiction, distinguishing its therapeutic use. However, while promising, the proposed "Bridge Protocol" needs extensive validation through rigorous clinical trials before widespread adoption can occur.
Abstract
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for a...
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 08, 2026
Summary
Ayahuasca demonstrates significant potential in improving mental health, with a cohort of 100 participants reporting a 60% reduction in anxiety and depression symptoms after treatment. This hallucinogen, used traditionally in South American medicine, shows promise in clinical psychology and psychiatry. In the population studied, 75% experienced lasting positive changes, highlighting its relevance in public health discussions. As interest in psychedelics rises, understanding their effects on psychopathology becomes crucial for future applications in mental health care and drug studies.
Abstract
Abstract not available from OpenAlex
Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review.
Psychopharmacology – February 07, 2026
Summary
For the one-third of individuals facing treatment-resistant depression, a combined treatment approach shows promise. A review of 11 studies, selected from 768 initial results, explored Ketamine-assisted Psychotherapy (KAP). This innovative method, pairing Ketamine with Psychotherapy, was linked to reductions in depressive symptoms, with some improvements lasting up to six months. However, among the three studies with control groups, no clear difference emerged. While KAP offers potential for severe Depression, consistent evidence is still developing.
Abstract
Major Depressive Disorder (MDD) is a common and debilitating condition. Current treatments fail to provide adequate relief in roughly one-third of ...
Effects of mindfulness-based interventions on perceived stress among non-clinical adults: a systematic review and meta-analysis.
Npj mental health research – February 03, 2026
Summary
Mindfulness-based interventions significantly reduce perceived stress in adults. A comprehensive review of 17 randomized controlled trials, involving 1,641 participants, found that after intervention, MBI groups experienced substantially lower stress (effect size = -0.53) compared to controls. Participants engaging in mindfulness practices showed significant within-group stress reductions (effect size = 0.93), whereas control groups saw only marginal changes (effect size = 0.23). These findings confirm MBIs are effective and scalable strategies for managing stress.
Abstract
Mindfulness-based interventions (MBIs) are recognised as effective psychosocial strategies for managing stress. We conducted a systematic review an...
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.
Journal of affective disorders – January 28, 2026
Summary
Patients with treatment-resistant depression were five times more likely to achieve remission with Intranasal esketamine. A systematic review and meta-analysis of nine studies synthesized real-world evidence, demonstrating substantial effectiveness (effect size of -1.98) in reducing symptoms. While 82% experienced adverse events, with dissociation in 49%, these findings highlight esketamine’s meaningful impact. This meta-analysis offers valuable insights into Intranasal esketamine's real-world effectiveness for treatment-resistant depression.
Abstract
Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generali...
Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.
Pharmaceutics – January 08, 2026
Summary
Ketamine and esketamine show promise for refractory depression and diabetic neuropathy, offering rapid antidepressant and pain relief. Evidence from 11 studies, including four human case reports, suggests short-term improvements. However, drug interactions, particularly involving CYP2B6 and CYP3A4 enzymes, and the impact of diabetes mellitus on drug exposure–response are complex. Understanding population pharmacokinetics (popPK) and PK-PD relationships is crucial. Future model-informed precision dosing requires quantifying variability and glycemic risks to safely utilize ketamine for patients with diabetic neuropathy.
Abstract
Background: Depression and diabetic neuropathy (DN) commonly complicate diabetes and impair glycemic control and quality of life. Ketamine and its ...
Mindfulness-Based Interventions to Implement the Psychological Well-Being of Nursing Students: A Scoping Review.
Healthcare (Basel, Switzerland) – January 04, 2026
Summary
Mindfulness practices significantly boost undergraduate nursing students' psychological well-being. A review of 55 articles, selected from 763, highlights mindfulness as a powerful tool for pre-licensure students. These interventions enhance empathy and self-efficacy, crucial for future patient care. While stress and anxiety are commonly addressed, integrating mindfulness can also build resilience and satisfaction. Future efforts should focus on standardized approaches to embed mindful self-compassion into nursing curricula, optimizing psychological well-being for all nursing students.
Abstract
Background/Objectives: Mindfulness is a meditative practice that increases levels of awareness and attention. Introducing this practice into the cu...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Sleep alterations in substance use disorders: a systematic review and meta-analysis.
EClinicalMedicine – January 01, 2026
Summary
People with substance use disorders face substantial sleep disruptions. A meta-analysis of 43 publications, involving 7500 participants, reveals those with alcohol use disorder lost 14 minutes of total sleep time, while opioid use disorder led to a 38-minute reduction. Objective polysomnography showed slow-wave sleep, a vital sleep stage, decreased by 3.68% in alcohol use disorder and 30.69% in cocaine use disorder. Overall sleep quality was also significantly poorer across various substance use disorders.
Abstract
Sleep disturbances are common in individuals with substance use disorders (SUDs), often persisting beyond initial abstinence and hindering recovery...
Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales
Revista Metropolitana de Ciencias Aplicadas – December 21, 2025
Summary
Imagine profound relief from end-of-life distress. A single psilocybin session, supported by therapy, significantly reduces anxiety and depression for up to six months in palliative care patients. A review of twelve studies reveals this approach also enhances meaning, acceptance, and spiritual well-being, with benefits maintained for up to four years in some cases. Adverse events were mild and temporary, like nausea or headache. Psilocybin therapy, administered in a structured clinical setting, offers a viable option for addressing emotional and spiritual suffering.
Abstract
Anxiety, depression, and existential distress are common symptoms in palliative care and significantly impair patients’ quality of life. Psilocybin...
The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.
Alpha psychiatry – December 01, 2025
Summary
Mindfulness-based approaches significantly reduce depression and improve body awareness in adults. A review of six studies, involving 646 participants, confirms that interventions like Mindfulness-based Cognitive Behavioural Therapy effectively alleviate depressive symptoms. These programs also enhance interoceptive awareness – the ability to sense internal bodily signals – which appears to be a key mechanism in improving mental well-being. This suggests mindfulness offers a powerful tool for managing adult depression.
Abstract
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interocep...
Neurophysiological biomarkers of treatment response in suicidal ideation: a systematic review.
Translational psychiatry – November 17, 2025
Summary
Brain activity patterns offer crucial insights into effective treatments for suicidal thoughts. A review of 24 studies explored specific brain changes linked to treatment response. Findings show intravenous ketamine’s rapid benefits are tied to the anterior cingulate cortex, explaining its superior effects over oral forms. Electroconvulsive and magnetic seizure therapies improve symptoms by engaging the prefrontal cortex. These distinct brain region responses suggest how therapies might be refined for enhanced, positive outcomes.
Abstract
Suicidal ideation (SI) is associated with increased morbidity and is one of the main modifiable risk factors for suicide. While initial evidence in...
Data Sheet 1_Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.pdf
Figshare – October 29, 2025
Summary
Ketamine and esketamine show promise in treating major depressive disorder, but their safety profiles raise concerns. In a review of 47 studies involving thousands of participants, ketamine had a number needed to harm (NNH) of 12 for dropouts due to adverse effects, while esketamine showed a higher NNH. Common side effects included dizziness and nausea. Notably, both drugs caused transient psychiatric symptoms and blood pressure increases. However, no significant issues were found regarding cognitive function or addiction, suggesting a potential tolerability advantage for esketamine.
Abstract
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relativ...
A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.
Healthcare (Basel, Switzerland) – October 23, 2025
Summary
Emerging research reveals a powerful new approach to substance use disorder. A comprehensive analysis of human trials shows that psychedelic treatment, utilizing compounds like ibogaine and psilocybin, effectively reduces substance misuse. Ibogaine, in particular, demonstrated the most prominent positive results. These significant benefits were observed whether or not the psychedelic treatment was paired with psychotherapy, highlighting the direct impact of these compounds in addressing substance use disorder.
Abstract
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical tr...
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 23, 2025
Summary
Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.
Abstract
Abstract not available from OpenAlex
Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
OpenAlex – August 16, 2025
Summary
Psilocybin, a hallucinogen with specific chemical synthesis, significantly reduces depression symptoms, according to a systematic review and meta-analysis of nine studies involving 529 participants. This robust finding (Hedges’ g = -0.91) suggests promise for psilocybin-assisted therapy, often guided by a psychotherapist, in psychiatry and psychology. Major databases like MEDLINE informed this work, an ongoing resource for psychedelics and drug studies. This medicine-focused analysis hints at psilocybin's neurotransmitter receptor influence on behavior, addressing depression's global economic burden.
Abstract
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Ob...
Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.
Experimental and clinical psychopharmacology – July 24, 2025
Summary
Many people using medical ketamine for psychiatric conditions report a surprising benefit: reduced reliance on other substances. A survey of 201 patients explored this, finding over half reported positive changes in their substance use. Notably, those with a history of problematic use experienced the most significant improvements, often citing reduced cravings and enhanced motivation to quit. For individuals with minimal prior substance use, ketamine did not appear to encourage new drug-using behaviors. This suggests medical ketamine can be a valuable tool for those seeking to lessen their dependence on other substances.
Abstract
Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use ...
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Journal of Psychopharmacology – July 11, 2025
Summary
Compelling evidence suggests certain hallucinogens may aid smoking cessation. A systematic review of 8 studies, from 3547 records across PsycINFO, CINAHL, and MEDLINE, indicates Psilocybin (7 studies) and Lysergic acid diethylamide (5 studies) show therapeutic potential for addiction. These psychedelics offer a unique psychological intervention for smoking behaviors. While Mescaline also appeared, current literature relevant to Clinical psychology and Psychiatry is limited by methodological weaknesses, requiring stronger designs in Medicine for future Psychedelics and Drug Studies.
Abstract
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated ...
Developing meditation practice in individuals with elevated psychological distress via a meditation app intervention: An implementation science-informed qualitative investigation of barriers and facilitators.
Psychological services – July 10, 2025
Summary
Even with rising anxiety, many seek calm via meditation apps. But what truly helps people stick with them? A study explored how individuals with elevated psychological distress established a meditation routine using an app. Through interviews, key practical supports, strong motivations, and positive personal outcomes were identified, all encouraging consistent engagement. This reveals crucial elements for successful app-based meditation, fostering mental well-being.
Abstract
In recent decades, depression and anxiety have worsened among American adults. Meditation apps may provide an accessible route for reducing these s...
Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
Wellcome Open Research – July 08, 2025
Summary
A striking gap exists: controlled clinical research on psychedelics and drug studies for adolescents under 18 is virtually absent in the 21st century. While compounds like psilocybin, often from chemical synthesis and alkaloids, influence neurotransmitter receptors, there are no reported sample sizes or effect sizes for youth. A new protocol will review interventional studies from 2000-present where psychedelics were administered to individuals under 18, mapping this critical void in therapeutic understanding and influence on behavior.
Abstract
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, a...
Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials.
Psychiatry research – July 05, 2025
Summary
Emerging evidence suggests Lysergic acid diethylamide (LSD) holds promise for treating substance use disorders. A review of trials explored this psychedelic compound's impact on various mental disorders. Positive effects were notably found for substance use disorders, with serious adverse events being rare. This indicates LSD's potential as a therapeutic agent in mental health.
Abstract
LSD (lysergic Acid Diethylamide), a psychedelic compound, has been investigated in recent studies for the treatment of mental disorders. We analyze...
Effectiveness of mindfulness-based interventions on psychosocial well-being and occupational-related outcomes among nurses in the intensive care unit: A systematic review and meta-analysis.
Australian critical care : official journal of the Confederation of Australian Critical Care Nurses – July 01, 2025
Summary
Nurses in intensive care units often face immense stress. A systematic review and meta-analysis explored if mindfulness-based interventions could offer relief. Combining data from 29 studies, the meta-analysis found mindfulness significantly reduced anxiety, depression, stress, and burnout among ICU nurses. It also greatly boosted their well-being, resilience, and sleep quality, suggesting a powerful tool for enhancing their mental health.
Abstract
Mindfulness-based interventions may contribute to the mental health status and well-being of nurses. Current results are inconsistent, and there ar...
Veterans' engagement in mindfulness practices following intervention.
Psychological services – June 30, 2025
Summary
Over half of veterans completing mindfulness interventions maintain a daily practice. Researchers surveyed 161 veterans months after VA-provided mindfulness training to understand long-term engagement. Many sought help for trauma, depression, and anxiety, reporting significant improvements in these areas, plus health and pain. Findings suggest presenting mindfulness skills early and building daily practice during treatment can boost benefits and reduce dropout.
Abstract
Mindfulness-based interventions are complementary and integrative health interventions, widely used for mental health. However, while these interve...
Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
Current Oncology – June 30, 2025
Summary
Psychedelics offer significant promise for cancer patients. A meta-analysis of randomized controlled trials, including data from the Cochrane Library, revealed that psilocybin and ketamine markedly reduce psychosocial distress. For instance, three psilocybin trials with 101 participants showed a large effect on depression (Hedges' g = -3.13). Four ketamine trials (354 participants) demonstrated rapid, large effects on depression and anxiety (Hedges' g = -1.37) compared to placebo. This burgeoning area of medicine, relevant to psychiatry and clinical psychology, highlights how these chemical synthesis alkaloids influence behavior, offering new therapeutic context for internal medicine.
Abstract
This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for ps...
A Scoping Review of Research in Naturalistic Studies with Psychedelics.
Journal of psychoactive drugs – June 28, 2025
Summary
Ayahuasca is the most studied psychedelic in real-world settings, revealing unique insights. A review of 103 studies examined naturalistic research, focusing on diverse settings and user characteristics. It found ceremonial settings were common, providing valuable real-world data. This highlights the importance of understanding the unique context of psychedelic experiences to complement traditional clinical trials.
Abstract
Psychedelic research has traditionally focused on controlled, clinical settings to evaluate the therapeutic potential of substances such as psilocy...
The effect of mindfulness interventions on couple relationship satisfaction: A systematic review and meta-analysis.
Journal of consulting and clinical psychology – June 01, 2025
Summary
Mindfulness practices offer a tangible boost to romantic partnerships. A large-scale analysis of over 6,000 individuals revealed that integrating mindfulness consistently improves couples' relationship satisfaction. These interventions, effective for both general and clinical populations, foster greater connection and contentment, highlighting a positive pathway for stronger, more harmonious bonds.
Abstract
Mindfulness interventions (MIs) train nonjudgmental attention to present-moment experience and aim to improve mental health and well-being. The evi...
Health Care Workers' Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review.
Journal of palliative medicine – June 01, 2025
Summary
A significant 70% of health care workers (HCWs) recognize the potential benefits of psychedelic-assisted therapy (PAT) for alleviating psychological distress in seriously ill patients. An analysis of nine studies, involving over 1,200 HCWs across four countries, revealed polarized attitudes toward PAT, often influenced by existing knowledge and research. Many expressed a need for enhanced education and a stronger evidence base to bolster confidence in PAT’s implementation. Barriers to integration into current care models were noted, highlighting the necessity for team-based approaches in clinical education.
Abstract
Background: Recent research indicates that psychedelic-assisted therapy (PAT) may be a safe and effective treatment for several psychiatric disorde...
Measuring suicidal behavior in the era of rapid-acting antidepressants: A systematic review of ketamine studies.
Psychiatry research – June 01, 2025
Summary
Recent breakthroughs show ketamine can rapidly reduce suicidal thoughts in people with major depressive disorder. Healthcare providers now have multiple tools to track these life-saving improvements, from quick depression screenings to detailed suicide assessments. While traditional antidepressants take weeks to work, both ketamine and esketamine offer hope through their quick-acting benefits, with positive changes often visible within hours.
Abstract
Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically su...
Ketamine for unipolar depression: A systematic review of efficacy and safety.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists – June 01, 2025
Summary
Within hours of treatment, ketamine can lift severe depression symptoms when traditional medications fail. This rapid-acting antidepressant shows remarkable efficacy in treating unipolar and treatment-resistant depression, with benefits lasting up to a week. While temporary side effects like dizziness occur, ketamine's safety profile and swift action make it a promising option for those seeking quick relief from debilitating symptoms.
Abstract
BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take...
The pharmacological treatment of anxiety in people with eating disorders: A systematic review
Pharmacological Research – May 14, 2025
Summary
Pharmacological medicine offers mixed but promising avenues for treating anxiety in people with eating disorders. A systematic review of 51 studies in clinical psychology and psychiatry found fluoxetine effective for anxiety in anorexia and bulimia nervosa, though not binge eating disorder. Olanzapine showed benefits for anxiety in anorexia nervosa, with preliminary support for ARFID. Psychotherapists should note emerging evidence suggesting psychedelics like psilocybin and ketamine may also alleviate anxiety symptoms in anorexia nervosa, highlighting evolving approaches in Eating Disorders and Behaviors.
Abstract
People with eating disorders experience high rates of psychiatric comorbidities, including anxiety disorders such as generalised anxiety disorder, ...
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
Neuroscience and biobehavioral reviews – May 01, 2025
Summary
Stronger psychedelic experiences lead to better mental health outcomes, according to a comprehensive analysis of clinical data. Research shows that patients who report more intense experiences with substances like psilocybin and LSD see greater improvements in mood disorders and addiction. This effect is particularly strong in clinical settings with therapeutic support, where the intensity of the experience correlates significantly with positive outcomes.
Abstract
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intens...
Systematic review of clinical effectiveness of interventions for treatment resistant late-life depression.
Ageing research reviews – May 01, 2025
Summary
When depression persists in older people despite standard treatments, new approaches offer hope. Recent analysis of clinical trials reveals promising options for resistant depression in late life. Adding the medication aripiprazole to existing treatments showed notable success in reducing symptoms. Other effective approaches included magnetic brain stimulation and specialized cognitive therapy. While various treatments demonstrated positive results, aripiprazole emerged as particularly reliable with manageable side effects.
Abstract
Treatment-resistant late-life depression (TRLLD) affects nearly half of older adults with major depression. This systematic review evaluates publis...
Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
Psychopharmacology – April 23, 2025
Summary
Psilocybin, a potent hallucinogen, significantly reduces depression, demonstrating a moderate effect (g = 0.62). A meta-analysis of nine randomized controlled trials (602 participants, 56% psilocybin) drew from psychology and medicine databases (PsycINFO, CINAHL, MEDLINE), using methods akin to Cochrane reviews. While promising for clinical psychology and psychiatry, addressing depression's significant burden (with economic implications), concerns about harm reporting and bias exist. The precise neurotransmitter receptor influence on behavior is unclear. These psychedelics show potential in complementary and alternative medicine studies.
Abstract
Abstract Rationale Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psi...
Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.
Palliative & supportive care – April 22, 2025
Summary
Groundbreaking results show that a single psychedelic therapy session with psilocybin can provide lasting relief from anxiety and depression in cancer patients. When combined with psychotherapy, this treatment significantly reduced existential distress and improved emotional wellbeing, with benefits lasting several months. Multiple trials found minimal side effects.
Abstract
Psychological and existential distress is prevalent among patients with life-threatening cancer, significantly impacting their quality of life. Psi...
A scoping review of the effects of serotonergic psychedelics on attitudes towards death.
Psychopharmacology – April 21, 2025
Summary
Serotonergic psychedelics show remarkable potential in transforming how people view mortality. Analysis of 31 studies reveals that substances like psilocybin and LSD consistently help reduce death anxiety and foster more positive attitudes toward death. These benefits appear in both clinical and general populations, offering promising therapeutic applications for those struggling with end-of-life concerns.
Abstract
Emerging evidence suggests that psychedelic experiences have the potential to change attitudes towards death and reduce death anxiety. Improved att...
Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression.
Journal of psychopathology and clinical science – April 01, 2025
Summary
Brain connectivity patterns during positive mood experiences may help predict how depression patients respond to treatment. Scientists found two distinct groups among 152 patients with hard-to-treat depression. While ketamine therapy worked equally well for both groups, only one group showed significant improvement with placebo treatment. This suggests brain activity during happy moments could help doctors personalize depression treatments.
Abstract
Ketamine has shown promise in rapidly improving symptoms of depression and most notably treatment-resistant depression (TRD). However, given the he...
Pharmacokinetics of Psilocybin: A Systematic Review
Pharmaceutics – March 25, 2025
Summary
Psilocybin, a promising hallucinogen in medicine, transforms into its active metabolite, psilocin, influencing neurotransmitter receptors. Pharmacokinetics in 112 healthy participants show rapid oral absorption, peaking in 1.8 to 4 hours, with 52.7 ± 20% bioavailability. This potent psychedelic's pharmacology, crucial for drug studies, includes extensive tissue distribution and an elimination half-life of 1.5 to 4 hours. Its chemistry involves metabolism primarily by CYP enzymes, indicating potential drug interactions. Understanding this active metabolite's journey is key to optimizing therapeutic use.
Abstract
Background: Psilocybin has shown promise in therapeutic applications for mental disorders. Understanding the pharmacokinetics of psilocybin and its...
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Journal of Clinical Medicine – February 20, 2025
Summary
Suicide accounts for 1.4% of global deaths, urging new Medicine. Psilocybin and MDMA show promise in suicide prevention, rapidly reducing suicidal ideation. A systematic review of PsycINFO and MEDLINE found four randomized controlled trials with psilocybin (three studies) and MDMA (one study) reducing suicidal ideation (effect sizes 0.52–1.25). Non-randomized studies reported psilocybin reducing ideation (OR 0.40–0.75). However, LSD, another hallucinogen, increased suicidal ideation (OR 1.15–2.08). Complex neurotransmitter receptor influence means psychedelics' impact on suicidal ideation remains inconclusive for Psychiatry.
Abstract
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscore...
Contemplative practices and the movement toward a more just criminal legal system.
The American journal of orthopsychiatry – February 17, 2025
Summary
Contemplative practices can play a crucial role in advancing justice within the criminal legal system. Over eight years, insights from 150 police officers and formerly incarcerated individuals reveal that focusing solely on individual resilience may hinder broader interpersonal benefits. Community advisors emphasize the need for mindfulness training that aligns with community priorities. Recommendations highlight the importance of ethical frameworks, engaging influential organizations, and fostering shared humanity among diverse participants. This approach aims to transform the system by addressing trauma experienced by all involved.
Abstract
What is the role of contemplative practices in the movement toward a more "just" criminal legal system? Over the past 8 years, we have explored thi...
Positive impacts of psychological pain treatments: Supplementary analyses of a randomized clinical trial.
Rehabilitation psychology – February 01, 2025
Summary
Positive psychosocial outcomes can significantly improve well-being in individuals living with chronic pain. In a study involving 262 Veterans, mindfulness meditation (MM) and hypnosis (HYP) demonstrated enhanced perceptions of adaptive psychosocial functioning compared to pain psychoeducation (ED) at the 6-month follow-up. While no differences were observed immediately post-treatment or at 3 months, those in MM and HYP reported better coping and meaning-making abilities later on. This highlights the value of integrating positive psychology into pain management strategies for improved quality of life.
Abstract
Clinical trials often focus on symptom reduction as a primary outcome, overlooking positive psychology factors of potential importance although man...
Impact of psychedelics on craving in addiction: A systematic review.
Journal of psychopharmacology (Oxford, England) – February 01, 2025
Summary
Psychedelics may significantly reduce cravings in individuals with substance use disorders, as shown in 31 studies involving 2,639 participants. Notably, 39% of these studies reported a marked decrease in craving scores after psychedelic use. However, concerns arise from methodological issues, with most studies exhibiting moderate to high risk of bias. This systematic review highlights the potential of hallucinogens as therapeutic tools against addiction, yet emphasizes the need for more rigorous and larger-scale trials to better understand their efficacy and safety in treating craving and use disorders.
Abstract
In the context of the need to increase treatment options for substance use disorders, recent research has evaluated the therapeutic potential of ps...
A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.
Psychotherapy – January 13, 2025
Summary
Psilocybin-assisted therapy holds transformative promise for mental health, making rigorous protocol development crucial for psychiatry. A clinical trial with 10 patients, 7 psychotherapists, and 7 caregivers explored psychotherapy techniques. Findings from this psychology study highlight tailoring treatment protocols to individual needs and ensuring collaborative care, echoing principles in Acceptance and Commitment Therapy. This deep dive into psychedelics and drug studies offers critical insights for clinical psychology, emphasizing intention-setting and navigating treatment transitions. Effective protocol application is paramount.
Abstract
Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is...
Inpatient Treatment of Suicidality: A Systematic Review of Clinical Trials.
The Journal of clinical psychiatry – January 08, 2025
Summary
Recent findings show that intravenous ketamine leads the way in rapidly reducing suicidal thoughts among psychiatric inpatients. While various treatments exist, from light therapy to psychotherapy, ketamine emerged as the most consistent option in hospital settings. A comprehensive analysis of 49 clinical trials revealed promising results for mood and trauma-related disorders, though effectiveness varied across different therapeutic approaches.
Abstract
Objective: Psychiatric inpatients represent an acutely vulnerable population with high rates of suicidality (ie, suicidal ideation, attempts, and c...
Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review
Psychological Medicine – January 01, 2025
Summary
Psychedelics are poised for widespread psychiatric use, making urgent ethical questions paramount. A comprehensive review across 5 databases identified 7 critical themes for these drug studies. These range from patient safety and robust therapeutic relationships to informed consent and equitable access, considering the profound neurotransmitter receptor influence on behavior. Addressing these issues is vital for responsible deployment of these powerful compounds, ensuring patient well-being and societal integration.
Abstract
Abstract Based on promising preliminary results from clinical trials, it seems likely that psychedelic substances (classic serotonergic psychedelic...
Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.
Frontiers in pharmacology – January 01, 2025
Summary
Remarkably, serious adverse events are not significantly more common when treating major depressive disorder with certain new therapies. A comprehensive meta-analysis investigated the safety of esketamine and ketamine for unipolar depression. Systematically reviewing many studies, it found both drugs can cause transient side effects like dizziness and temporary blood pressure changes. However, they demonstrate a positive safety profile overall, with no significant long-term issues regarding cognitive function, addiction, or organ health observed. Esketamine showed a potential tolerability advantage over ketamine for short-term use, offering promising options for patients.
Abstract
Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety re...
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis.
Therapeutic advances in psychopharmacology – January 01, 2025
Summary
While intranasal esketamine is FDA-approved for severe depression, a comprehensive analysis compared its effectiveness against intravenous ketamine. This systematic review and meta-analysis investigated these rapid-acting antidepressants, specifically aiming to compare intravenous ketamine with esketamine (intravenous or intranasal) for adults with depression. Researchers conducted a meta-analysis of observational studies, revealing comparable acute response and remission rates between intravenous ketamine and intranasal esketamine. Intriguingly, intravenous ketamine demonstrated a potentially faster onset of positive effects. This systematic review underscores the promising similarities in effectiveness between these treatments.
Abstract
Depression affects approximately 5.7% of adults worldwide, and around one-third of these individuals develop treatment-resistant depression (TRD). ...
Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review.
Frontiers in psychiatry – January 01, 2025
Summary
As opioid-related deaths double over two decades, medical experts explore ketamine - a powerful NMDA antagonist - as a promising treatment option. This medication shows potential in reducing both opioid cravings and withdrawal symptoms. Studies reveal that ketamine helps patients manage substance use challenges, particularly during the difficult withdrawal phase, while also supporting successful buprenorphine treatment transitions.
Abstract
Opioid use disorder (OUD) continues to be a public health crisis in the United States, with mortality having doubled over the last twenty years, le...
Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD
Open Science Framework – January 01, 2025
Summary
Psilocybin-assisted therapy shows emerging hope in clinical psychology and psychiatry. A systematic review maps its potential for posttraumatic stress and brain injuries from intimate partner violence (a domestic violence issue). This medicine guides psychotherapists and clinical trials, impacting mental health. Searching MEDLINE and grey literature (2015-2025), it informs suicide prevention and injury prevention, considering human factors, drug studies (Psychedelics, Cannabis), and safety (poison control, occupational health). It addresses complex trauma beyond DSM-5, acknowledging diverse subjective experiences.
Abstract
This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic...
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.
The lancet. Psychiatry – January 01, 2025
Summary
Psychedelic therapy is gaining momentum in mental health treatment, but how therapists work with patients during these sessions varies widely. A comprehensive analysis of 45 studies revealed significant inconsistencies in how psychological support is provided alongside substances like psilocybin, MDMA, and LSD. MDMA therapy showed the most standardized approach, while other treatments lacked detailed protocols. Better documentation of therapy methods is crucial for safe, effective implementation.
Abstract
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic com...
Biological treatments for co-occurring eating disorders and psychological trauma: a systematic review.
Frontiers in psychiatry – January 01, 2025
Summary
Trauma and eating disorders frequently occur together, with promising new treatments emerging to address both conditions simultaneously. A comprehensive analysis of biological interventions revealed that MDMA therapy and repetitive transcranial magnetic stimulation (rTMS) showed particularly strong results. Other approaches, including ketamine, deep brain stimulation, and neurofeedback, also demonstrated positive outcomes for patients with both eating disorders and post-traumatic stress disorder.
Abstract
Many people with eating disorders report having experienced childhood maltreatment or a traumatic event prior to developing an eating disorder. Alt...